Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:AKR1C3-AKR1E2

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: AKR1C3-AKR1E2
	FusionPDB ID: 3448
	FusionGDB2.0 ID: 3448
		Hgene	Tgene
	Gene symbol	AKR1C3	AKR1E2
	Gene ID	8644	83592
	Gene name	aldo-keto reductase family 1 member C3	aldo-keto reductase family 1 member E2
	Synonyms	DD3\|DDX\|HA1753\|HAKRB\|HAKRe\|HSD17B5\|PGFS\|hluPGFS	AKR1CL2\|AKRDC1\|LoopADR\|TAKR\|hTSP\|htAKR
	Cytomap	10p15.1	10p15.1
	Type of gene	protein-coding	protein-coding
	Description	aldo-keto reductase family 1 member C33-alpha hydroxysteroid dehydrogenase, type II3-alpha-HSD type II, brainchlordecone reductase homolog HAKRbdihydrodiol dehydrogenase 3dihydrodiol dehydrogenase Xindanol dehydrogenaseprostaglandin F synthasetest	1,5-anhydro-D-fructose reductaseAF reductasealdo-keto reductase family 1 member C-like protein 2aldo-keto reductase family 1, member C-like 2aldo-keto reductase loopADRtestis aldo-keto reductasetestis-specific protein
	Modification date	20200320	20200313
	UniProtAcc	P42330 Main function of 5'-partner protein: FUNCTION: Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Acts as a NAD(P)(H)-dependent 3-, 17- and 20-ketosteroid reductase on the steroid nucleus and side chain and regulates the metabolism of androgens, estrogens and progesterone (PubMed:10622721, PubMed:11165022, PubMed:7650035, PubMed:9415401, PubMed:9927279). Displays the ability to catalyze both oxidation and reduction in vitro, but most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentration of NADPH (PubMed:14672942, PubMed:11165022). Acts preferentially as a 17-ketosteroid reductase and has the highest catalytic efficiency of the AKR1C enzyme for the reduction of delta4-androstenedione to form testosterone (PubMed:20036328). Reduces prostaglandin (PG) D2 to 11beta-prostaglandin F2, progesterone to 20alpha-hydroxyprogesterone and estrone to 17beta-estradiol (PubMed:15047184, PubMed:20036328, PubMed:10622721, PubMed:11165022, PubMed:10998348, PubMed:19010934). Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha-androstan-3-alpha,17-beta-diol (3-alpha-diol) (PubMed:10998348, PubMed:14672942, PubMed:11165022, PubMed:7650035, PubMed:9415401, PubMed:10557352). Displays also retinaldehyde reductase activity toward 9-cis-retinal (PubMed:21851338). {ECO:0000269\|PubMed:10557352, ECO:0000269\|PubMed:10622721, ECO:0000269\|PubMed:10998348, ECO:0000269\|PubMed:11165022, ECO:0000269\|PubMed:14672942, ECO:0000269\|PubMed:15047184, ECO:0000269\|PubMed:19010934, ECO:0000269\|PubMed:20036328, ECO:0000269\|PubMed:21851338, ECO:0000269\|PubMed:7650035, ECO:0000269\|PubMed:9415401, ECO:0000269\|PubMed:9927279}.	Q96JD6 Main function of 5'-partner protein: FUNCTION: Catalyzes the NADPH-dependent reduction of 1,5-anhydro-D-fructose (AF) to 1,5-anhydro-D-glucitol (By similarity). Has low NADPH-dependent reductase activity towards 9,10-phenanthrenequinone (in vitro) (PubMed:12604216, PubMed:15118078). {ECO:0000250\|UniProtKB:Q9DCT1, ECO:0000269\|PubMed:12604216, ECO:0000269\|PubMed:15118078}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000380554, ENST00000439082, ENST00000605149, ENST00000470862,	ENST00000334019, ENST00000345253, ENST00000525281, ENST00000532248, ENST00000298375,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	2 X 3 X 2=12	6 X 3 X 6=108
	# samples	3	8
	** MAII score	log2(3/12*10)=1.32192809488736 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0	log2(8/108*10)=-0.432959407276106 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: AKR1C3 [Title/Abstract] AND AKR1E2 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: AKR1C3 [Title/Abstract] AND AKR1E2 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	AKR1C3(5144842)-AKR1E2(4877867), # samples:1 AKR1C3(5139742)-AKR1E2(4872867), # samples:1
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	AKR1C3	GO:0007186	G protein-coupled receptor signaling pathway	18508192
Hgene	AKR1C3	GO:0008284	positive regulation of cell proliferation	18508192\|20036328
Hgene	AKR1C3	GO:0010942	positive regulation of cell death	21787718
Hgene	AKR1C3	GO:0016488	farnesol catabolic process	21187079
Hgene	AKR1C3	GO:0034614	cellular response to reactive oxygen species	21787718
Hgene	AKR1C3	GO:0042448	progesterone metabolic process	21232532
Hgene	AKR1C3	GO:0042574	retinal metabolic process	21851338
Hgene	AKR1C3	GO:0048385	regulation of retinoic acid receptor signaling pathway	21851338
Hgene	AKR1C3	GO:0051897	positive regulation of protein kinase B signaling	18508192
Hgene	AKR1C3	GO:0055114	oxidation-reduction process	16983398\|19442656\|21232532
Hgene	AKR1C3	GO:0071276	cellular response to cadmium ion	21787718
Hgene	AKR1C3	GO:0071277	cellular response to calcium ion	22170488
Hgene	AKR1C3	GO:0071379	cellular response to prostaglandin stimulus	22170488
Hgene	AKR1C3	GO:0071384	cellular response to corticosteroid stimulus	19336506
Hgene	AKR1C3	GO:0071395	cellular response to jasmonic acid stimulus	19487289
Hgene	AKR1C3	GO:0071799	cellular response to prostaglandin D stimulus	18508192
Hgene	AKR1C3	GO:1900053	negative regulation of retinoic acid biosynthetic process	21851338
Hgene	AKR1C3	GO:2000353	positive regulation of endothelial cell apoptotic process	19442656
Hgene	AKR1C3	GO:2000379	positive regulation of reactive oxygen species metabolic process	19442656
Tgene	AKR1E2	GO:0055114	oxidation-reduction process	15118078

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:5144842/chr10:4877867)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across AKR1C3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across AKR1E2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000605149	AKR1C3	chr10	5144842	+	ENST00000298375	AKR1E2	chr10	4877867	+	2273	1102	325	1740	471
ENST00000439082	AKR1C3	chr10	5144842	+	ENST00000298375	AKR1E2	chr10	4877867	+	2130	959	182	1597	471
ENST00000380554	AKR1C3	chr10	5144842	+	ENST00000298375	AKR1E2	chr10	4877867	+	2669	1498	652	2136	494
ENST00000605149	AKR1C3	chr10	5139742	+	ENST00000298375	AKR1E2	chr10	4872867	+	2081	625	325	1548	407
ENST00000439082	AKR1C3	chr10	5139742	+	ENST00000298375	AKR1E2	chr10	4872867	+	1938	482	182	1405	407
ENST00000380554	AKR1C3	chr10	5139742	+	ENST00000298375	AKR1E2	chr10	4872867	+	2477	1021	652	1944	430

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000605149	ENST00000298375	AKR1C3	chr10	5144842	+	AKR1E2	chr10	4877867	+	0.001116619	0.9988834
ENST00000439082	ENST00000298375	AKR1C3	chr10	5144842	+	AKR1E2	chr10	4877867	+	0.001442648	0.9985574
ENST00000380554	ENST00000298375	AKR1C3	chr10	5144842	+	AKR1E2	chr10	4877867	+	0.000434898	0.99956506
ENST00000605149	ENST00000298375	AKR1C3	chr10	5139742	+	AKR1E2	chr10	4872867	+	0.00061322	0.9993868
ENST00000439082	ENST00000298375	AKR1C3	chr10	5139742	+	AKR1E2	chr10	4872867	+	0.000788401	0.99921155
ENST00000380554	ENST00000298375	AKR1C3	chr10	5139742	+	AKR1E2	chr10	4872867	+	0.000628977	0.999371

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for AKR1C3-AKR1E2

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
AKR1C3	chr10	5139742	AKR1E2	chr10	4872867	1021	121	DYVDLYLIHSPMSLKASPGKVTEAVK
AKR1C3	chr10	5139742	AKR1E2	chr10	4872867	482	98	DYVDLYLIHSPMSLKASPGKVTEAVK
AKR1C3	chr10	5139742	AKR1E2	chr10	4872867	625	98	DYVDLYLIHSPMSLKASPGKVTEAVK
AKR1C3	chr10	5144842	AKR1E2	chr10	4877867	1102	258	AKSYNEQRIRQNVQPPHPEWIMSCSE
AKR1C3	chr10	5144842	AKR1E2	chr10	4877867	1498	281	AKSYNEQRIRQNVQPPHPEWIMSCSE
AKR1C3	chr10	5144842	AKR1E2	chr10	4877867	959	258	AKSYNEQRIRQNVQPPHPEWIMSCSE

Top

Potential FusionNeoAntigen Information of AKR1C3-AKR1E2 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

AKR1C3-AKR1E2_5139742_4872867.msa
AKR1C3-AKR1E2_5144842_4877867.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:06	IHSPMSLKA	0.9971	0.7343	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:22	YLIHSPMSL	0.9944	0.5816	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:11	YLIHSPMSL	0.9922	0.6408	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:24	YLIHSPMSL	0.9917	0.629	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:67	YLIHSPMSL	0.9917	0.629	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:30	YLIHSPMSL	0.9917	0.629	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:60	YLIHSPMSL	0.9916	0.5941	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:01	IHSPMSLKA	0.9905	0.8732	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A30:08	LIHSPMSLK	0.9904	0.6434	6	15
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A30:08	MSLKASPGK	0.9899	0.8313	11	20
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:21	YLIHSPMSL	0.9894	0.7423	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:16	YLIHSPMSL	0.9864	0.5557	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:27	YLIHSPMSL	0.9861	0.6641	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:04	YLIHSPMSL	0.9832	0.5776	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:13	YLIHSPMSL	0.9827	0.738	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B38:02	IHSPMSLKA	0.9824	0.9515	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B38:01	IHSPMSLKA	0.9821	0.9401	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:35	YLIHSPMSL	0.9731	0.649	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:29	YLIHSPMSL	0.9645	0.6367	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:38	YLIHSPMSL	0.9591	0.6537	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B08:01	YLIHSPMSL	0.9588	0.5676	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:20	YLIHSPMSL	0.9501	0.6308	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:13	SLKASPGKV	0.9467	0.6878	12	21
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:25	YLIHSPMSL	0.9261	0.9303	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B08:09	YLIHSPMSL	0.922	0.6257	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:02	YLIHSPMSL	0.92	0.9411	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B14:02	YLIHSPMSL	0.8986	0.7567	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B14:01	YLIHSPMSL	0.8986	0.7567	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:10	YLIHSPMSL	0.7113	0.5847	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:01	YLIHSPMSL	0.6741	0.9404	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B13:01	YLIHSPMSL	0.3136	0.921	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:18	IHSPMSLKA	0.3132	0.5699	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:06	LIHSPMSLKA	0.4316	0.7439	6	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:06	YLIHSPMSLKA	0.5543	0.7611	5	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C06:03	YLIHSPMSL	0.9981	0.9948	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C12:04	YLIHSPMSL	0.9981	0.9936	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C12:12	YLIHSPMSL	0.9981	0.9467	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:07	YLIHSPMSL	0.9927	0.625	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:19	YLIHSPMSL	0.9925	0.9915	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C12:16	YLIHSPMSL	0.9922	0.9636	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:01	YLIHSPMSL	0.9917	0.629	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:09	IHSPMSLKA	0.9915	0.5289	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:07	YLIHSPMSL	0.9901	0.9805	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:08	YLIHSPMSL	0.9858	0.9389	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:04	YLIHSPMSL	0.984	0.9273	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C15:06	YLIHSPMSL	0.9829	0.9283	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C04:06	YLIHSPMSL	0.9794	0.8971	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:05	IHSPMSLKA	0.9775	0.8478	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C08:13	YLIHSPMSL	0.9744	0.9555	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C08:04	YLIHSPMSL	0.9744	0.9555	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C04:14	YLIHSPMSL	0.9651	0.7708	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C04:10	YLIHSPMSL	0.948	0.7204	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C04:07	YLIHSPMSL	0.9432	0.719	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C05:09	YLIHSPMSL	0.9414	0.9298	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C02:06	YLIHSPMSL	0.9377	0.961	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:21	YLIHSPMSL	0.9236	0.8795	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B14:03	YLIHSPMSL	0.921	0.7903	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C08:03	YLIHSPMSL	0.9178	0.9808	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C01:17	YLIHSPMSL	0.8458	0.9341	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:13	YLIHSPMSL	0.8058	0.9096	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:29	YLIHSPMSL	0.7765	0.9486	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C08:15	YLIHSPMSL	0.7748	0.9647	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:05	YLIHSPMSL	0.7704	0.9696	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:14	YLIHSPMSL	0.7685	0.9774	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:09	YLIHSPMSL	0.7389	0.5852	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:10	YLIHSPMSL	0.73	0.9495	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:12	YLIHSPMSL	0.709	0.9451	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:80	YLIHSPMSL	0.7055	0.9234	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:67	YLIHSPMSL	0.7055	0.9234	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:10	YLIHSPMSL	0.6991	0.9573	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:46	YLIHSPMSL	0.6866	0.8272	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:27	YLIHSPMSL	0.647	0.9469	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C01:30	YLIHSPMSL	0.6284	0.9527	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:19	YLIHSPMSL	0.6043	0.6566	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:95	YLIHSPMSL	0.5567	0.6895	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B73:01	IHSPMSLKA	0.1696	0.5616	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C12:03	YLIHSPMSL	0.9983	0.9798	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C12:02	YLIHSPMSL	0.9976	0.963	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C06:17	YLIHSPMSL	0.996	0.9934	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C06:02	YLIHSPMSL	0.996	0.9934	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:03	YLIHSPMSL	0.9959	0.9909	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:04	YLIHSPMSL	0.9959	0.9909	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:03	YLIHSPMSL	0.9931	0.7405	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:03	SLKASPGKV	0.9924	0.6504	12	21
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:67	YLIHSPMSL	0.9921	0.9847	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:31	IHSPMSLKA	0.9912	0.8732	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:17	YLIHSPMSL	0.9908	0.9594	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A30:01	MSLKASPGK	0.9899	0.9364	11	20
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:06	YLIHSPMSL	0.9894	0.7423	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A02:14	YLIHSPMSL	0.9894	0.6507	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:05	YLIHSPMSL	0.9888	0.9214	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-A30:01	LIHSPMSLK	0.9883	0.7704	6	15
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:02	YLIHSPMSL	0.9842	0.9555	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C03:06	YLIHSPMSL	0.9823	0.9906	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B38:05	IHSPMSLKA	0.9821	0.9401	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C06:06	YLIHSPMSL	0.979	0.9755	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C15:05	YLIHSPMSL	0.9778	0.9314	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:73	YLIHSPMSL	0.9771	0.9222	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C15:02	YLIHSPMSL	0.9733	0.9006	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C04:04	YLIHSPMSL	0.9715	0.8645	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B08:18	YLIHSPMSL	0.9588	0.5676	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C16:02	YLIHSPMSL	0.9478	0.9894	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C04:03	YLIHSPMSL	0.9467	0.7883	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C04:01	YLIHSPMSL	0.9432	0.719	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C05:01	YLIHSPMSL	0.9414	0.9298	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:30	YLIHSPMSL	0.9374	0.7889	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C18:01	YLIHSPMSL	0.9342	0.7397	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:39	YLIHSPMSL	0.9239	0.8248	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C08:01	YLIHSPMSL	0.9178	0.9808	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C01:03	YLIHSPMSL	0.8952	0.9126	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C14:03	YLIHSPMSL	0.8939	0.9431	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C14:02	YLIHSPMSL	0.8939	0.9431	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C02:10	YLIHSPMSL	0.8897	0.9709	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C02:02	YLIHSPMSL	0.8897	0.9709	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C06:08	YLIHSPMSL	0.8795	0.9821	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C01:02	YLIHSPMSL	0.8496	0.929	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:04	YLIHSPMSL	0.8478	0.9349	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B08:12	YLIHSPMSL	0.8438	0.7622	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C17:01	YLIHSPMSL	0.8297	0.8591	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B35:13	YLIHSPMSL	0.822	0.9154	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B07:13	YLIHSPMSL	0.8198	0.8257	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:22	YLIHSPMSL	0.7922	0.7684	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C08:02	YLIHSPMSL	0.7748	0.9647	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:02	YLIHSPMSL	0.7228	0.9379	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:02	YLIHSPMSL	0.7055	0.9234	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:17	YLIHSPMSL	0.6921	0.9602	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C07:01	YLIHSPMSL	0.5523	0.6624	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B39:11	IHSPMSLKA	0.496	0.6588	7	16
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-B15:09	YLIHSPMSL	0.473	0.5341	5	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C14:02	LYLIHSPMSL	0.9654	0.9437	4	14
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	1021	HLA-C14:03	LYLIHSPMSL	0.9654	0.9437	4	14
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:01	NVQPPHPEW	0.9752	0.9794	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A30:08	RIRQNVQPP	0.9488	0.7453	7	16
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B58:01	NVQPPHPEW	0.9349	0.9527	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B58:02	NVQPPHPEW	0.8934	0.9679	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:17	NVQPPHPEW	0.8683	0.8594	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B53:01	NVQPPHPEW	0.8575	0.5981	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:16	NVQPPHPEW	0.8079	0.8134	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A31:08	NVQPPHPEW	0.7745	0.5462	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:03	NVQPPHPEW	0.7638	0.986	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A32:13	NVQPPHPEW	0.6546	0.985	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A24:17	NVQPPHPEW	0.5726	0.6495	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A24:15	NVQPPHPEW	0.5197	0.6918	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A24:14	VQPPHPEWI	0.4182	0.7281	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B52:01	VQPPHPEWI	0.1208	0.9981	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:01	QNVQPPHPEW	0.9982	0.9945	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B58:02	QNVQPPHPEW	0.9912	0.9937	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B58:01	QNVQPPHPEW	0.9874	0.9918	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:03	QNVQPPHPEW	0.9689	0.9982	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A32:13	QNVQPPHPEW	0.5715	0.9832	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:01	RQNVQPPHPEW	0.9993	0.9814	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A31:08	RQNVQPPHPEW	0.9972	0.7471	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B58:02	RQNVQPPHPEW	0.9967	0.9847	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B58:01	RQNVQPPHPEW	0.9907	0.9569	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:03	RQNVQPPHPEW	0.9903	0.9795	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:16	RQNVQPPHPEW	0.9892	0.8424	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:17	RQNVQPPHPEW	0.9873	0.8973	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A32:13	RQNVQPPHPEW	0.9778	0.9411	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B73:01	QRIRQNVQP	0.9831	0.7976	6	15
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A02:07	VQPPHPEWI	0.4888	0.77	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C01:17	VQPPHPEWI	0.1708	0.9764	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C01:30	VQPPHPEWI	0.1611	0.981	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B48:03	VQPPHPEWI	0.1338	0.835	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C07:29	VQPPHPEWI	0.0988	0.9742	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C07:13	VQPPHPEWI	0.0769	0.9671	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C03:14	NVQPPHPEW	0.0263	0.9884	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B73:01	QRIRQNVQPP	0.9779	0.7731	6	16
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B44:08	QNVQPPHPEW	0.862	0.7976	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B44:08	RQNVQPPHPEW	0.9897	0.6336	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:24	VQPPHPEW	0.9982	0.9791	12	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:10	NVQPPHPEW	0.9752	0.9794	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:04	NVQPPHPEW	0.9642	0.6323	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B58:06	NVQPPHPEW	0.923	0.9031	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:13	NVQPPHPEW	0.8936	0.7442	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:02	NVQPPHPEW	0.816	0.9172	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A32:01	NVQPPHPEW	0.7669	0.9778	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B53:02	NVQPPHPEW	0.748	0.8592	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A25:01	NVQPPHPEW	0.5911	0.9096	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C06:17	VQPPHPEWI	0.5187	0.9956	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C06:02	VQPPHPEWI	0.5187	0.9956	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C06:06	VQPPHPEWI	0.5123	0.9947	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:24	NVQPPHPEW	0.3962	0.9121	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C01:03	VQPPHPEWI	0.2559	0.9804	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C06:08	VQPPHPEWI	0.2273	0.9936	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C01:02	VQPPHPEWI	0.1871	0.9763	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B40:12	VQPPHPEWI	0.1338	0.835	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-C07:04	VQPPHPEWI	0.1082	0.975	12	21
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B51:06	NVQPPHPEW	0.0581	0.8276	11	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:10	QNVQPPHPEW	0.9982	0.9945	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:04	QNVQPPHPEW	0.9912	0.908	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B58:06	QNVQPPHPEW	0.9851	0.9822	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:02	QNVQPPHPEW	0.9575	0.988	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:24	QNVQPPHPEW	0.9338	0.9448	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:13	QNVQPPHPEW	0.8595	0.9	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A32:01	QNVQPPHPEW	0.7611	0.9887	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A25:01	QNVQPPHPEW	0.2274	0.9568	10	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B15:24	RQNVQPPHPEW	0.9995	0.8676	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:10	RQNVQPPHPEW	0.9993	0.9814	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:04	RQNVQPPHPEW	0.9982	0.854	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-A32:01	RQNVQPPHPEW	0.9966	0.9724	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B58:06	RQNVQPPHPEW	0.9951	0.9491	9	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	HLA-B57:02	RQNVQPPHPEW	0.974	0.9618	9	20

Top

Potential FusionNeoAntigen Information of AKR1C3-AKR1E2 in HLA II

AKR1C3-AKR1E2_5144842_4877867.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	DRB3-0201	NEQRIRQNVQPPHPE	4	19
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	DRB3-0201	EQRIRQNVQPPHPEW	5	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	DRB3-0204	NEQRIRQNVQPPHPE	4	19
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	DRB3-0204	EQRIRQNVQPPHPEW	5	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	DRB3-0204	YNEQRIRQNVQPPHP	3	18
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	DRB3-0214	NEQRIRQNVQPPHPE	4	19
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	DRB3-0214	EQRIRQNVQPPHPEW	5	20
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	DRB3-0224	NEQRIRQNVQPPHPE	4	19
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	1498	DRB3-0224	EQRIRQNVQPPHPEW	5	20

Top

Fusion breakpoint peptide structures of AKR1C3-AKR1E2

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
5102	LIHSPMSLKASPGK	AKR1C3	AKR1E2	chr10	5139742	chr10	4872867	1021

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
7539	QRIRQNVQPPHPEW	AKR1C3	AKR1E2	chr10	5144842	chr10	4877867	1498

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of AKR1C3-AKR1E2

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	5102	LIHSPMSLKASPGK	-7.9962	-8.1096
HLA-B14:02	3BVN	5102	LIHSPMSLKASPGK	-5.70842	-6.74372
HLA-B52:01	3W39	5102	LIHSPMSLKASPGK	-6.83737	-6.95077
HLA-B52:01	3W39	5102	LIHSPMSLKASPGK	-4.4836	-5.5189
HLA-A11:01	4UQ2	5102	LIHSPMSLKASPGK	-10.0067	-10.1201
HLA-A11:01	4UQ2	5102	LIHSPMSLKASPGK	-9.03915	-10.0745
HLA-A24:02	5HGA	5102	LIHSPMSLKASPGK	-6.56204	-6.67544
HLA-A24:02	5HGA	5102	LIHSPMSLKASPGK	-5.42271	-6.45801
HLA-B44:05	3DX8	5102	LIHSPMSLKASPGK	-7.85648	-8.89178
HLA-B44:05	3DX8	5102	LIHSPMSLKASPGK	-5.3978	-5.5112
HLA-A02:01	6TDR	5102	LIHSPMSLKASPGK	-3.37154	-4.40684
HLA-B14:02	3BVN	7539	QRIRQNVQPPHPEW	-7.9962	-8.1096
HLA-B14:02	3BVN	7539	QRIRQNVQPPHPEW	-5.70842	-6.74372
HLA-B52:01	3W39	7539	QRIRQNVQPPHPEW	-6.83737	-6.95077
HLA-B52:01	3W39	7539	QRIRQNVQPPHPEW	-4.4836	-5.5189
HLA-A11:01	4UQ2	7539	QRIRQNVQPPHPEW	-10.0067	-10.1201
HLA-A11:01	4UQ2	7539	QRIRQNVQPPHPEW	-9.03915	-10.0745
HLA-A24:02	5HGA	7539	QRIRQNVQPPHPEW	-6.56204	-6.67544
HLA-A24:02	5HGA	7539	QRIRQNVQPPHPEW	-5.42271	-6.45801
HLA-B44:05	3DX8	7539	QRIRQNVQPPHPEW	-7.85648	-8.89178
HLA-B44:05	3DX8	7539	QRIRQNVQPPHPEW	-5.3978	-5.5112
HLA-A02:01	6TDR	7539	QRIRQNVQPPHPEW	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of AKR1C3-AKR1E2

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	11	20	MSLKASPGK	CTAAAGGCTTCTCCAGGGAAAGTGACC
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	12	21	SLKASPGKV	AAGGCTTCTCCAGGGAAAGTGACCGAG
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	4	14	LYLIHSPMSL	CTTATTCATTCTCCAATGTCTCTAAAGGCT
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	5	14	YLIHSPMSL	ATTCATTCTCCAATGTCTCTAAAGGCT
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	5	16	YLIHSPMSLKA	ATTCATTCTCCAATGTCTCTAAAGGCTTCTCCA
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	6	15	LIHSPMSLK	CATTCTCCAATGTCTCTAAAGGCTTCT
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	6	16	LIHSPMSLKA	CATTCTCCAATGTCTCTAAAGGCTTCTCCA
AKR1C3-AKR1E2	chr10	5139742	chr10	4872867	7	16	IHSPMSLKA	TCTCCAATGTCTCTAAAGGCTTCTCCA
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	10	20	QNVQPPHPEW	AACGTGCAGCCTCCTCATCCAGAATGGATC
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	11	20	NVQPPHPEW	GTGCAGCCTCCTCATCCAGAATGGATC
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	12	20	VQPPHPEW	CAGCCTCCTCATCCAGAATGGATC
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	12	21	VQPPHPEWI	CAGCCTCCTCATCCAGAATGGATCATG
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	6	15	QRIRQNVQP	CGCATCAGACAGAACGTGCAGCCTCCT
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	6	16	QRIRQNVQPP	CGCATCAGACAGAACGTGCAGCCTCCTCAT
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	7	16	RIRQNVQPP	ATCAGACAGAACGTGCAGCCTCCTCAT
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	9	20	RQNVQPPHPEW	CAGAACGTGCAGCCTCCTCATCCAGAATGGATC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	3	18	YNEQRIRQNVQPPHP	AATGAGCAGCGCATCAGACAGAACGTGCAGCCTCCTCATCCAGAA
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	4	19	NEQRIRQNVQPPHPE	GAGCAGCGCATCAGACAGAACGTGCAGCCTCCTCATCCAGAATGG
AKR1C3-AKR1E2	chr10	5144842	chr10	4877867	5	20	EQRIRQNVQPPHPEW	CAGCGCATCAGACAGAACGTGCAGCCTCCTCATCCAGAATGGATC

Top

Information of the samples that have these potential fusion neoantigens of AKR1C3-AKR1E2

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
LUSC	AKR1C3-AKR1E2	chr10	5144842	ENST00000380554	chr10	4877867	ENST00000298375	TCGA-66-2759-01A
LUSC	AKR1C3-AKR1E2	chr10	5139742	ENST00000380554	chr10	4872867	ENST00000298375	TCGA-68-A59J-01A

Top

Potential target of CAR-T therapy development for AKR1C3-AKR1E2

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to AKR1C3-AKR1E2

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to AKR1C3-AKR1E2

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)